Eugenio Morelli, MD1,2,3, Anil Aktas-Samur, PhD3,4*, Domenico Maisano, PhD, MSc3,4*, Claire Gao, BS4*, Vanessa Favasuli, PhD4*, Dimitrios Papaioannou, MD5, Na Liu, MS4*, Marcello Turi, PhD1*, Pietro Folino, M.Sc6*, Laure Vreux, Ph.D.7,8*, Michela Cumerlato, MS4*, Liang Cheng, MS7*, Iannis Aifantis, PhD9, Mariateresa Fulciniti, PhD4, Kenneth C. Anderson, MD10, Annamaria Gulla, MD1, Mehmet K. Samur, PhD4 and Nikhil C. Munshi, MD4
1Candiolo Cancer Institute FPO-IRCCS, Candiolo, Italy
2Department of Medical Oncology, University of Turin, Turin, Italy
3equally contributed, #, Italy
4Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA
5Perlmutter Cancer Center, Department of Medicine, Division of Hematology/Oncology, NYU Grossman School of Medicine, New York, NY, New York, NY
6Dana Farber Cancer Institute, Boston, MA
7Medical Oncology, Dana-Farber Cancer Institute, Boston
8Harvard Medical School, Boston
9Department of Pathology, NYU Grossman School of Medicine, New York, NY
10Dana Farber Cancer Institute, Harvard Medical School, Boston, MA